Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 706 to 720 of 1688 results for carers

  1. Aflibercept for untreated retinopathy in babies born preterm TS ID 11943

      Status ...

    Technology appraisal guidance
    Topic selection

  2. Ustekinumab for the treatment of moderately to severely active Crohn's disease in children [TS ID 11955]

      Status ...

    Technology appraisal guidance
    Topic selection

  3. Larotrectinib for treating NTRK fusion-positive solid tumours (MA review of TA630) [ID6292]

    Awaiting development [GID-TA11565] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Abatacept for treating active idiopathic inflammatory myopathies TS ID 10095

    Awaiting development [GID-TA10993] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Budesonide–glycopyrronium–formoterol fumarate for treating severe asthma in people 12 years and over TS ID 12018

      Status ...

    Technology appraisal guidance
    Topic selection

  6. Vosoritide for treating achondroplasia in people 4 months and over ID6488

    Awaiting development [GID-TA11528] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Odevixibat for treating progressive familial intrahepatic cholestasis (HST17)

    Evidence-based recommendations on odevixibat (Bylvay) for treating progressive familial intrahepatic cholestasis in people 6 months and older.

    Highly specialised technologies guidance
    Published
    22 February 2022
    View recommendations

    Sections for HST17

  8. Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]

    Awaiting development [GID-TA11366] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. How we develop NICE guidelines

    The guidance development timeline

  10. Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]

    Awaiting development [GID-TA11100] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Oral semaglutide for managing overweight and obesity [ID6188]

    Awaiting development [GID-TA11149] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Apadamtase alfa for preventing and treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]

    Awaiting development [GID-TA11130] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]

    Awaiting development [GID-TA11137] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]

    Awaiting development [GID-TA11365] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]

    Awaiting development [GID-TA11326] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development